RT, one of conventional treatment modalities actively being used for PDAC, can cause immunogenic cell death, which activates innate responses including the receptor for advanced glycation endproducts (RAGE) and TLR2/4 pathways and subsequently modifies the TME by promoting the release of tumor antigens and chemokines that recruit inflammatory cells into the TME. The gene discussed is TLR2; the disease is neoplasm.